Equillium, Inc. - Common Stock (NQ:EQ)

1.414 -0.026 (-1.83%)

Delayed Quote Updated: 9:49 AM EDT, Oct 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Equillium, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Equillium Announces Publication of Abstract for the Annual Congress of the European Hematology Association

May 12, 2022

From Equillium, Inc.

Via Business Wire

Equillium Announces Three Poster Presentations at the Annual Meeting of The American Association of Immunologists

May 09, 2022

From Equillium, Inc.

Via Business Wire

Equillium Announces Three Poster Presentations at the Transplantation & Cellular Meetings of the ASTCT and CIBMTR

April 25, 2022

From Equillium, Inc.

Via Business Wire

Equillium Announces Oral Presentation at the Italian Society of Experimental Hematology

April 04, 2022

From Equillium, Inc.

Via Business Wire

Equillium Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate & Clinical Development Updates

March 23, 2022

From Equillium, Inc.

Via Business Wire

Equillium Announces Two Oral Presentations at the Annual Meeting of the European Society for Blood and Marrow Transplantation

March 23, 2022

From Equillium, Inc.

Via Business Wire

Equillium's Itolizumab Shows Durable Clinical Response In GvHD Patients ↗

March 23, 2022

Equillium Inc (NASDAQ: EQ) announced two oral presentations on itolizumab at the Annual Meeting of the European Society for Blood and Marrow Transplantation.

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

March 17, 2022

Thursday saw 34 companies set new 52-week lows. Facts of Interest About Today's 52-Week Lows: SecureWorks (NASDAQ:SCWX) was the largest company by market cap to...

Via Benzinga

Equillium Adds Three Drugs To Its Pipeline Via Bioniz Acquisition ↗

February 16, 2022

Equillium Inc (NASDAQ: EQ), with only one asset in its pipeline, is expanding its drug development efforts via the acquisition of Bioniz Therapeutics. The deal,...

Via Benzinga

Equillium Acquires Bioniz Therapeutics Significantly Expanding Pipeline of Novel Immunomodulatory Drug Candidates

February 16, 2022

From Equillium, Inc.

Via Business Wire

Equillium Provides Timing Update on Conference Presentations

February 15, 2022

From Equillium, Inc.

Via Business Wire

Equillium to Present at the SVB Leerink Virtual Global Healthcare Conference

February 09, 2022

From Equillium, Inc.

Via Business Wire

12 Health Care Stocks Moving In Friday's After-Market Session ↗

January 21, 2022

Gainers Mustang Bio (NASDAQ:MBIO) shares ...

Via Benzinga

Equillium Announces Multiple Abstracts Accepted for Presentation at the Transplantation & Cellular Meetings of ASTCT and CIBMTR

January 10, 2022

From Equillium, Inc.

Via Business Wire

Equillium to Present at the H.C. Wainwright Virtual BioConnect Conference

January 05, 2022

From Equillium, Inc.

Via Business Wire

10 Biggest Price Target Changes For Wednesday ↗

January 05, 2022

UBS cut the price target for Adobe Inc. (NASDAQ: ADBE) from $635 to $575. Adobe shares fell 2.3% to $541.06 in pre-market trading. SVB Leerink lowered the price target on...

Via Benzinga

45 Biggest Movers From Yesterday ↗

January 05, 2022

Gainers ATA Creativity Global (NASDAQ: AACG) gained 114.3% to close at $2.55. Hoth Therapeutics, Inc. (NASDAQ: HOTH) surged 85.7% to settle at $1.30 after the company announced...

Via Benzinga

Equillium Announces Publication of Data in the Journal of Clinical Investigation Highlighting the Importance of the CD6-ALCAM Pathway in the Pathogenesis of Lupus Nephritis

January 04, 2022

From Equillium, Inc.

Via Business Wire

Equillium To Reassess Potential For Its Asthma Trials ↗

January 04, 2022

Equillium Inc's (NASDAQ: EQ) Phase 1b EQUIP study of itolizumab in patients with uncontrolled asthma met its primary objective. The data demonstrated an on-target...

Via Benzinga

Equillium Announces Data from Phase 1b EQUIP Study in Patients with Uncontrolled Asthma

January 04, 2022

From Equillium, Inc.

Via Business Wire

Equillium Announces Additional Patient Data at ASH 2021 Demonstrating Continued Positive and Durable Clinical Responses in Acute Graft-Versus-Host Disease Patients Treated with Itolizumab

December 13, 2021

From Equillium, Inc.

Via Business Wire

Equillium Reports Third Quarter 2021 Financial Results and Provides Clinical Development Updates

November 10, 2021

From Equillium, Inc.

Via Business Wire

Equillium to Present at Two Upcoming Investor Conferences

November 09, 2021

From Equillium, Inc.

Via Business Wire

Equillium Presents Clinical Data from EQUALISE Phase 1b Study in Lupus Patients at the American Society of Nephrology Annual Meeting

November 05, 2021

From Equillium, Inc.

Via Business Wire

Equillium Presents Interim Safety Data from First Cohort of Asthma Patients in Phase 1b EQUIP Study at the American College of Allergy, Asthma & Immunology Meeting

November 05, 2021

From Equillium, Inc.

Via Business Wire

Equillium Announces Two Abstracts Accepted for Presentation at the 63rd ASH Annual Meeting and Exposition

November 04, 2021

From Equillium, Inc.

Via Business Wire

Equillium Reveals Early Safety Data For Itolizumab In Lupus Patients ↗

November 02, 2021

Equillium Inc (NASDAQ: EQ) announced interim data from the Type A portion of the Phase 1b EQUALISE study in systemic lupus erythematosus (SLE) patients. Data were...

Via Benzinga

Equillium Announces Interim Safety Data and Reduction in Proteinuria for Lupus Patients Treated with Itolizumab in the EQUALISE Study Presented at the ACR Annual Meeting

November 02, 2021

From Equillium, Inc.

Via Business Wire

Equillium Announces Two Abstracts Accepted for Presentation at the Upcoming Virtual 2021 American Society of Nephrology Annual Meeting

October 18, 2021

From Equillium, Inc.

Via Business Wire

The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline ↗

October 31, 2021

Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.